actinic keratosis, nonthrombocytopenic purpura, melanin hyperpigmentation, cutis laxa senilis, leukoderma, skin changes due to chronic exposure to nonionizing radiation
Conditions
Interventions
24 research's subjects will be treated with 0.05% retinoic acid in the extensor surface of a forearm 3 alternate nights a week, and will be submitted to 8 series and biweekly peels of retinoic acid at
Drug
Q20.040
D02.455.326.271.665.202.495.818.500
Sponsors
Universidade Federal de São Paulo
Unidade de Cosmiatria, Cirurgia e Oncologia do Departamento de Dermatologia da Universidade Federal de São Paulo
Instituto de Ciências Ambientais, Químicas e Farmacêuticas da Universidade Federal de São Paulo
Eligibility
Age
60 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy women that past menopause and were not hormone replacement of any kind, over the age of 60; phototypes II and III according to Fitzpatrick's classification (1988) (Appendix 2); presence of superficial actinic keratoses and multiple through proposed score on the scale of Guimarães (2015) (Appendix 3); agreement to avoid sun exposure throughout the study; agreement with the conditions of study, ability to understand and strictly follow the guidelines received, willingness to attend the regular review and signature of IC (Appendix 1).
Exclusion criteria
Exclusion criteria: Local treatment, except sunscreens, with tretinoin for at least 6 months, other retinoids, alpha-hydroxy acids, polyhydroxy acids, beta-hydroxy acids and ascorbic acid for at least 3 months; previous treatment with oral retinoid in the last 6 months; previous treatment with superficial chemical peels, microdermabrasion and laser non-ablative, for a period not exceeding three months; presence of infectious or inflammatory dermatoses in the upper limbs; chemotherapy in the last three months; clinical evidence of immunosuppression.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement of photodamaged skin of the forearm, supported by additional tests (photographic scale, noninvasive assays, histological and immunohistochemical findings) after topical treatment with retinoic acid, but with a statistically significant difference between the two therapeutic models (0.05% vs. 5%). | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences between the two tolerability therapeutic models (0.05% vs. 5%), evaluated clinically and by means of noninvasive tests (corneometry, for example). | — |
Countries
Brazil
Contacts
Public ContactJuliana Sumita
Universidade Federal de São Paulo
Outcome results
None listed